South African court blocks pharmacy accused of selling unapproved Ozempic-style weight-loss drugs

Novo Nordisk wins interim order barring SA rival from selling Ozempic copies

Novo Nordisk won a court order blocking iDexis from selling unregistered semaglutide; iDexis produced 84,500 monthly units, exceeding combined Novo sales. The ruling tightens IP protection and supply-chain transparency for pharma manufacturing, raising compliance standards in emerging markets.